IKBKB and cancer: Notably, among these compounds are TPCA-1, an inhibitor of the IκB kinase subunit IKKβ (IKK2), which reduces the production of several proinflammatory cytokines and impedes NF-κB signaling; PF-56227, a well-established focal adhesion kinase (FAK) inhibitor; mirin, a compound characterized as 6-(4-hydroxyphenyl)-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone; and linsitinib, an experimental drug candidate aimed at treating diverse cancer types.